Vanucizumab
Vanucizumab (pronunciation: va-nu-ci-zu-mab) is a biopharmaceutical drug that is used in the treatment of various types of cancer. It is a monoclonal antibody that is designed to inhibit the growth of cancer cells by blocking the action of certain proteins in the body.
Etymology
The name "Vanucizumab" is derived from the Latin "vanus" meaning empty, and "cizumab", a common suffix for monoclonal antibodies. The "empty" reference is indicative of the drug's mechanism of action, which involves emptying the body of cancer cells.
Mechanism of Action
Vanucizumab works by binding to two different proteins, VEGF (Vascular Endothelial Growth Factor) and Ang2 (Angiopoietin-2). These proteins are involved in the growth and spread of cancer cells. By blocking these proteins, Vanucizumab can help to slow down the growth and spread of the cancer.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- VEGF: A protein that stimulates the formation of blood vessels.
- Ang2: A protein that is involved in the growth and spread of cancer cells.
- Biopharmaceutical: A type of drug that is produced using biotechnology.
See Also
External links
- Medical encyclopedia article on Vanucizumab
- Wikipedia's article - Vanucizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski